| 15.32 -0.035 (-0.23%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.25 | 1-year : | 23.59 |
| Resists | First : | 18.19 | Second : | 20.2 |
| Pivot price | 16.63  |
|||
| Supports | First : | 14.94 | Second : | 12.43 |
| MAs | MA(5) : | 15.62 |
MA(20) : | 16.9 |
| MA(100) : | 16.29 |
MA(250) : | 17.23 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 12.4 |
D(3) : | 15.5 |
| RSI | RSI(14): 32.5 |
|||
| 52-week | High : | 25 | Low : | 13.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PLSE ] has closed above bottom band by 11.2%. Bollinger Bands are 16.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.95 - 16.07 | 16.07 - 16.15 |
| Low: | 14.89 - 15.03 | 15.03 - 15.15 |
| Close: | 15.12 - 15.32 | 15.32 - 15.47 |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Mon, 10 Nov 2025
Pulse Biosciences (PLSE) Is Down 7.9% After FDA OK for Cardiac Device Trials and Q3 Losses – Has the Bull Case Changed? - Yahoo Finance
Fri, 07 Nov 2025
Pulse Biosciences (PLSE): Evaluating Valuation After Recent Share Price Decline - Sahm
Fri, 07 Nov 2025
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2025 Earnings Call Transcript - Insider Monkey
Thu, 06 Nov 2025
Pulse Biosciences Q3 2025 Earnings Call Highlights - TipRanks
Thu, 06 Nov 2025
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences - Business Wire
Thu, 06 Nov 2025
Decoding Pulse Biosciences Inc (PLSE): A Strategic SWOT Insight - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 67 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 74.2 (%) |
| Held by Institutions | 9 (%) |
| Shares Short | 2,450 (K) |
| Shares Short P.Month | 2,540 (K) |
| EPS | -1.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.54 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -56.2 % |
| Return on Equity (ttm) | -103.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -14.19 |
| PEG Ratio | 0 |
| Price to Book value | 9.88 |
| Price to Sales | 0 |
| Price to Cash Flow | -23.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|